Anatomical Therapeutic Chemical • L01XC12 • brentuximab vedotin

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L01A Alkylating agents

L01B Antimetabolites

L01C Plant alkaloids and other natural products

L01D Cytotoxic antibiotics and related substances

L01E Protein kinase inhibitors

L01F Monoclonal antibodies and antibody drug conjugates

L01X Other antineoplastic agents

L01XA Platinum compounds

L01XB Methylhydrazines

L01XC Monoclonal antibodies

L01XC04 alemtuzumab Indicated for: multiple sclerosis; chronic lymphocytic leukemia

L01XC12 brentuximab vedotin Indicated for: lymphoma

L01XC16 dinutuximab beta Indicated for: cancer

L01XC19 blinatumomab Indicated for: leukemia

L01XC27 olaratumab Indicated for: cancer

L01XC31 avelumab Indicated for: cancer

L01XD Sensitizers used in photodynamic/radiation therapy

L01XF Retinoids for cancer treatment

L01XG Proteasome inhibitors

L01XH Histone deacetylase (HDAC) inhibitors

L01XJ Hedgehog pathway inhibitors

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

L01XL Antineoplastic cell and gene therapy

L01XM Isocitrate dehydrogenase (IDH) inhibitors

L01XU Other antineoplastic agents (cont.)

L01XX Other antineoplastic agents

L01XY Combinations of antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various